KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 856.95%.

  • Xenon Pharmaceuticals' EBITDA Margin changed N/A to 856.95% in Q1 2025 from the same period last year, while for Sep 2025 it was 4213.83%, marking a year-over-year change of. This contributed to the annual value of 1368.91% for FY2022, which is 9404600.0% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported EBITDA Margin of 856.95% as of Q1 2025.
  • Xenon Pharmaceuticals' EBITDA Margin's 5-year high stood at 198.14% during Q1 2022, with a 5-year trough of 29632.58% in Q3 2022.
  • Its 3-year average for EBITDA Margin is 4861.85%, with a median of 760.8% in 2025.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' EBITDA Margin was 1703500bps (2022), while the steepest drop was -292859500bps (2022).
  • Xenon Pharmaceuticals' EBITDA Margin (Quarter) stood at 664.65% in 2021, then tumbled by -4358bps to 29632.58% in 2022, then skyrocketed by 97bps to 856.95% in 2025.
  • Its last three reported values are 856.95% in Q1 2025, 29632.58% for Q3 2022, and 5813.06% during Q2 2022.